Tamoxifen citrate 英文名称: Tamoxifen citrate | ||||||||||||||||||||||||||||||||||||||||||||||||
型号:null 产品货号: IHR1032-0050MG | ||||||||||||||||||||||||||||||||||||||||||||||||
价格:请致电:010-57128832,18610462672 | ||||||||||||||||||||||||||||||||||||||||||||||||
品牌: gene operation | ||||||||||||||||||||||||||||||||||||||||||||||||
IHR1032-Tamoxifen citrate TAMOXIFEN CITRATE(Nolvadex), >99 % 【英文同义名】:TMX citrate, ICI-46474, Nolvadex® , Istubal®, Valodex®, Tamodex® 【中文同义名】:塔莫西酚 订购信息:(原装进口,常备现货)
产品描述 Tamoxifen citrate (同义名: TMX citrate, ICI-46474, Nolvadex® , Istubal®, Valodex®, Tamodex® ) 是Tamoxifen的枸橼酸盐,是选择性Estrogen receptor(ER)(雌***受体)调控剂。Tamoxifen在乳腺中表现出拮抗功能,而在其它组织,如子宫内膜中是一种激动剂。Tamoxifen抑制SR31747与重组mSI和his的结合,IC50分别为1.9 nM和3.6 nM。Tamoxifen选择性抑制哺乳动物SI细胞中的甾醇生成[1]。Tamoxifen提高乳腺癌中VEGF mRNA表达,在体内实验中,却降低MCF-7移植瘤小鼠中细胞外VEGF水平。Tamoxifen辅助治疗雌***依赖的乳腺癌,可以阻止肿瘤细胞转移,并提高病人存活[2]。Tamoxifen还可以降低女性血清中LDL胆固醇,已经用于女性乳腺癌的治疗。 靶点
化学特性
储存液配制
结构式使用浓度(仅作参考)Tamoxifen citrate的具体使用浓度请参考相关文献,并根据自身实验条件(如实验目的,细胞种类,培养特性等)进行摸索和优化。 参考文献[1] Clarke M, et al. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet. 351(9114):1451-67 (1998). [2] Johnson MD, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl ***, a novel active metabolite of ***. Breast Cancer Research and Treatment 85(2):151-9 (2004). [3] Gottardis MM, et al. Contrasting actions of *** on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48(4):812-5 (1988). [4] Love RR, et al. Effects of *** on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 326(13):852-6 (1992). [5] Guetta V, et al. Effects of the antiestrogen *** on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol. 76(14):1072-3 (1995). [6] Thomas P, et al. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 146(2):624-32 (2005). [7] OBrian CA, et al. Inhibition of protein kinase C by ***. Cancer Res. 45(6):2462-5 (1985). |